Literature DB >> 15354013

Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas.

Brian F O'Reilly1, Ameet Kishore, John A Crowther, Colin Smith.   

Abstract

OBJECTIVE: To examine the relationship between growth rate of vestibular schwannomas and the expression of various growth factor receptors. STUDY
DESIGN: Retrospective case review of clinical growth rate in conjunction with a histopathologic and immunohistochemical reexamination of archival specimens.
SETTING: A tertiary referral neurotologic center. PATIENTS: Three groups: a historical group to act as controls, consisting of 30 patients with sporadic vestibular schwannomas removed before the unit adopted an initial interval scan policy; a group of 14 patients with sporadic vestibular schwannomas who had undergone an initial interval scan policy, showed radiologic evidence of growth, and therefore had their schwannoma removed; and a group of 16 schwannomas removed from 11 neurofibromatosis Type 2 patients. MAIN OUTCOME MEASURES: A comparison between the three clinical groups using immunohistochemical studies to determine the level of expression of the proliferation factor Ki-67, c-erbB-2, and c-erbB-3 receptors and fibroblastic growth factor receptors 1 and 4.
RESULTS: The level of expression of the proliferation factor Ki-67 was very low and similar in all three groups. C-erbB-2 and c-erbB-3 receptors were not expressed in any of the groups. fibroblastic growth factor receptor 4 expression was not significantly different, but there was a variation in the expression of fibroblastic growth factor receptor 1 between the three groups that correlated well with the differing incidence of growth in the groups. The increase in expression of fibroblastic growth factor receptor 1 in the neurofibromatosis Type 2 group was not statistically significant, but the increase in expression of fibroblastic growth factor receptor 1 in the growing sporadic group was statistically significant when compared with the historical controls. The level of fibroblastic growth factor receptor 1 expression correlates significantly with the rate of growth as measured on interval magnetic resonance imaging.
CONCLUSIONS: Overexpression of fibroblastic growth factor receptor 1 has a positive correlation with the incidence and the rate of growth of sporadic vestibular schwannomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354013     DOI: 10.1097/00129492-200409000-00024

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  11 in total

1.  Vestibular schwannoma and pituitary adenoma in the same patient: coincidence or novel clinical association?

Authors:  Matthew L Carlson; Neil S Patel; Amy E Glasgow; Elizabeth B Habermann; Brandon R Grossardt; Michael J Link
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

2.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

3.  Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Authors:  Scott R Plotkin; Chris Halpin; Michael J McKenna; Jay S Loeffler; Tracy T Batchelor; Fred G Barker
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

4.  Management of large and giant vestibular schwannomas.

Authors:  Irumee Pai; James Bowman; Nick Thomas; Neil Kitchen; Anthony Strong; Rupert Obholzer; Michael Gleeson
Journal:  Skull Base       Date:  2011-11

5.  BDNF mRNA expression is significantly upregulated in vestibular schwannomas and correlates with proliferative activity.

Authors:  Frauke Kramer; Timo Stöver; Athanasia Warnecke; Marc Diensthuber; Thomas Lenarz; Kirsten Wissel
Journal:  J Neurooncol       Date:  2009-11-25       Impact factor: 4.130

6.  The fate of spinal schwannomas following subtotal resection: a retrospective multicenter study by the Korea spinal oncology research group.

Authors:  Seil Sohn; Chun Kee Chung; Sung-Hye Park; Eun-Sang Kim; Ki-Jeong Kim; Chi Heon Kim
Journal:  J Neurooncol       Date:  2013-06-30       Impact factor: 4.130

7.  Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma.

Authors:  Dustin M Dalgorf; Corwyn Rowsell; Juan M Bilbao; Joseph M Chen
Journal:  Skull Base       Date:  2008-11

8.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20

9.  Subtotal resection of vestibular schwannoma: Evaluation with Ki-67 measurement, magnetic resonance imaging, and long-term observation.

Authors:  Giannicola Iannella; Marco de Vincentiis; Cira Di Gioia; Raffaella Carletti; Benedetta Pasquariello; Alessandra Manno; Diletta Angeletti; Ersilia Savastano; Giuseppe Magliulo
Journal:  J Int Med Res       Date:  2017-04-27       Impact factor: 1.671

10.  Primary Neurilemmoma of the Thyroid Gland Clinically Mimicking Malignant Thyroid Nodule.

Authors:  Young Sub Lee; Jee Soon Kim; Arthur Minwoo Chung; Woo Chan Park; Tae-Jung Kim
Journal:  J Pathol Transl Med       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.